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ABSTRACT Ginkgo biloba extract (GBE) and anthocyanins are considered beneficial for various vascular diseases. This
study was performed to evaluate the effect of GBE and anthocyanins on visual function in patients with normal tension
glaucoma (NTG) based on the vascular theory of mechanisms of glaucomatous optic nerve damage. Retrospective analysis
was carried out by a chart review of 332 subjects (209 men and 123 women) who were treated with anthocyanins (n= 132),
GBE (n = 103), or no medication (control, n = 97). Humphrey Visual Field (HVF) test, logarithm of the minimal angle of
resolution best-corrected visual acuity (logMAR BCVA), intraocular pressure, blood pressure, and fasting blood glucose were
determined before and after treatment. Complete ocular and systemic examinations were performed. The mean follow-up
duration was 23.82 – 9.84 (range, 12–59) months; the mean anthocyanin treatment duration was 24.32– 10.43 (range, 6–53)
months, and the mean GBE treatment duration was 23.81– 10.36 months (range, 6–59) months. After anthocyanin treatment,
the mean BCVA for all eyes improved from 0.16 ( – 0.34) to 0.11 ( – 0.18) logMAR units (P = .008), and HVF mean
deviation improved from - 6.44 ( – 7.05) to - 5.34 ( – 6.42) (P= .001). After GBE treatment, HVF mean deviation improved
from - 5.25 ( – 6.13) to - 4.31 ( – 5.60) (P = .002). A generalized linear model demonstrated that the final BCVA was not
affected by demographic differences among the groups. These results suggest that anthocyanins and GBE may be helpful in
improving visual function in some individuals with NTG.
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INTRODUCTION
Normal tension glaucoma (NTG) is a form of open-angle glaucoma in which damages to the optic nerve
and visual field are present, despite normal intraocular
pressure (IOP).1 The exact mechanisms of the anatomic and
functional damage in NTG are still unknown, but two the-
ories of how NTG occurs are the vascular theory (reduced
blood flow to the optic nerve) and the mechanical theory
(relatively high IOP).2 Some patients with NTG continue to
have visual field damage despite medical therapy or surgical
procedures. Therefore, the pathogenic role of other factors
warrants consideration.3 Retinal ganglion cell loss is the
main process of glaucomatous optic nerve and is triggered by
various factors, including depletion of neurotrophin,4 glu-
tamate neuroexcitotoxicity,5–9 ischemia,10 nitric oxide and
the formation of reactive oxygen species,11 autoimmune
processes,12 and inflammation.13
Based on these theories, Ginkgo biloba extract (GBE) is
used for numerous retinal disorders and glaucoma. GBE is
also used by patients with peripheral vascular disease and to
treat cerebral insufficiency.14 Mechanisms of action of GBE
have been described: (1) effects on blood circulation, such
as vasoregulatory activity and rheological effects (decreased
viscosity and antagonism of platelet-activating factor re-
ceptors); (2) metabolic changes, for example, effects on
neuron metabolism such as increased tolerance to anoxia;
(3) beneficial effects on neurotransmitter disturbances; and
(4) prevention of damage to cell membranes caused by free
radicals.14
In addition to GBE, anthocyanins from Vaccinium
myrtillus or bilberry are increasingly being used in oph-
thalmology. In fact, V. myrtillus has a long history of
medical use.15 The active components, flavonoid antho-
cyanosides (anthocyanins), have a particular affinity for the
eye and vascular tissues.16 Several mechanisms of action of
anthocyanins have been described: (1) strong antioxidant
properties17; (2) stabilization of collagen fibers and pro-
motion of collagen biosynthesis18,19; (3) decreased capillary
permeability and fragility20; (4) inhibition of platelet ag-
gregation21; (5) prevention of the release and synthesis of
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proinflammatory compounds such as histamine, prosta-
glandins, and leukotrienes18,19,22; and (6) lower blood glu-
cose levels.23
Recently, favorable effects of anthocyanins and GBE
have been reported, although the quality of most of these
investigations is questionable. Based on the reported fa-
vorable effects of anthocyanins and GBE on blood circula-
tion and their antioxidative effects, anthocyanins and GBE
are used by clinicians to treat patients with NTG and dia-
betic retinopathy.24,25 Therefore, we aimed to evaluate the
effects of anthocyanins and GBE on the general visual
function of patients with NTG.
MATERIALS AND METHODS
We first performed a retrospective study with a chart re-
view. Subjects with a 12-month or more follow-up were
recruited from the outpatient glaucoma service of the De-
partment of Ophthalmology, Kangbuk Samsung Hospital,
Seoul, Korea, from January 2005 to December 2010. This
study was performed in adherence with the Declaration of
Helsinki and after approval from the Institutional Review
Board and Ethics Committee of the Kangbuk Samsung
Hospital in Seoul, Korea. We studied 332 consecutive pa-
tients (664 eyes), 209 men and 123 women (mean age, 52.90
years; range, 20–89 years), who had monocular/binocular
NTG. Among 332 consecutive NTG patients, 132 patients
were assigned to the anthocyanin treatment group, 103 to the
GBE treatment group, and 97 to the control (nontreatment)
group. The control patients consisted of subjects who had
monocular/binocular NTG and were recruited during the
same period at the same center.
All subjects underwent a full medical and ocular history
and a detailed ocular examination, including visual acuity,
IOP measurement using the Goldman applanation tonome-
ter, the Humphrey visual field (HVF) test, red-free disc
photo, stereo disc photo, optical coherence tomography
(OCT) examination, gonioscopy, slit-lamp examination, and
fundus examination. Systolic and diastolic blood pressure
and fasting blood glucose were measured.
Included were patients with a diagnosis of NTG, defined
as optic disc abnormalities consistent with glaucomatous
optic neuropathy with or without visual field loss. Glauco-
matous optic disc abnormality was defined as neuroretinal
rim thinning, notching, excavation, or a retinal nerve fiber
layer (RNFL) defect. Glaucomatous visual field loss was
defined as a pattern standard deviation outside 95% normal
limits or a glaucoma hemifield test result that was not
within normal limits and abnormally high sensitivity, con-
firmed with two or more consecutive more visual field tests.
Other inclusion criteria for both normal and glaucomatous
subjects were (1) IOP of 21-mm Hg or less without topical
hypotensive therapy (highest values recorded during diurnal
measurements, made from 9 AM to 5 PM, every 2 h by the
Goldmann applanation tonometer at first visit); (2) 20 years
or older; (3) logarithm of the minimal angle of resolution
best-corrected visual acuity (logMAR BCVA) 0.70 or bet-
ter; (4) no history of amblyopia; (5) no history of ocular or
neurologic disease or surgery that might cause test results or
vision changes that confound recognition of a test result
solely due to glaucoma; and (6) mental and physical ca-
pacity to perform the tests. Exclusion criteria were (1) active
ocular disease; (2) use of other ocular medications or ther-
apies that might have a substantial effect on IOP; (3) history
of ocular surgery; or (4) use of other similar systemic
medications (e.g., ergoloid mesylate derivative).
The anthocyanin product used in the study was V. myr-
tillus extract (Kukje Pharma Ind. Co., Ltd., Gyeonggi-do,
Korea). The anthocyanin product was provided in the form
of capsule; each capsule contained anthocyanins 60.0mg.
The GBE product used in the study was Gingko leaf extract
(SK Chemicals Co., Ltd., Gyeonggi-do, Korea), which is
composed of ginkgo flavones glycosides and terpenelactons
from the Gingko leaf. GBE was provided in the form a tablet
containing 80.0mg of the GBE. The subjects were instructed
to take one capsule or tablet after breakfast and supper, two
capsules or tablets daily. Patients were surveyed using a
questionnaire to assess the duration of actual intakes of an-
thocyanins and GBE for the treatment duration analysis.
The HVF Analyzer, BCVA, IOP, blood pressure, fasting
blood glucose, RNFL thickness, stereoscopic disc photog-
raphy were performed at every visit, and complete ocular
and systemic examinations were performed.
Visual field examinations of both eyes were performed by
an experienced technician using the HVF Analyzer (Carl
Zeiss Meditec, Dublin, CA, USA) with the 30-2 SITA
standard algorithm at each visit. For analysis, the average of
the last two of the three visual field examinations within the
first six months was compared with the visual field exami-
nations of the last two visits. For unreliable tests, the subject
was excluded from the analysis. After the first six months, a
follow-up examination was performed within four to six
months. In the HVF, the mean deviation is a measure of the
average difference from the normal expected value for that
age. Therefore, negative values denote decreased overall
visual field sensitivity.26 The pattern standard deviation is
the standard deviation of the mean difference between the
threshold value at each test location and the expected normal
value. It is a measure of the extent to which the threshold
determinations at different locations in the visual field differ
from each other. Therefore, positive high values mean that
there is a localized loss, possibly indicating glaucoma.26
The BCVA was checked at every visit, and all visual
acuity values were converted to the logarithm of the mini-
mal angle of resolution for statistical analysis. The logMAR
scale converts the geometric sequence of a traditional chart
to a linear scale. Positive values indicate vision loss,
whereas negative values indicate normal or better visual
acuity.27
IOP and blood pressure and fasting blood glucose were
recorded before and after treatment (a single measurement
was taken at the same time of the day for all phases of the
trial).
Complete ocular examinations and questionnaires that
addressed ocular or systemic complications were performed
at every visit.
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Statistical methods
Baseline demographic and clinical parameters were
compared among treatment groups using a one-way analysis
of variance (ANOVA). Paired t-tests compared differences
before and after medication with baseline values within
treatment groups. In addition, a generalized linear model
was used to assess the relationship between final visual
acuity and multiple variables. All data were analyzed using
the SPSS statistical software system version 18.0 (SPSS,
Inc., Chicago, IL, USA). A P value of < .05 was considered
statistically significant. In cases of bilateral NTG, only the
right eye was considered.
RESULTS
Investigated were 332 patients (332 eyes) of which 209
were men and 123 were women. The mean age was
52.90 – 13.74 years (range, 20–89 years). The mean follow-
up duration was 23.82– 9.84 months (range, 12–59 months),
and 78 patients (23.4%) had diabetes mellitus, and 103
(30.9%) had hypertension (Table 1).
Groups were 132 patients in the anthocyanin treatment
group, 103 in the GBE group, and 97 in the control (non-
treatment) group. Significant differences among the three
groups were mean age (one-way ANOVA, P < .001), dia-
stolic/systolic blood pressure (one-way ANOVA, P = .006,
P = .026, respectively), but not fasting blood glucose (one-
way ANOVA, P = .156), diabetes mellitus (one-way
ANOVA, P = .814), or hypertension (one-way ANOVA,
P = .662) prevalence rates (Table 2). The mean anthocyanin
treatment duration (actual duration of intake from the pa-
tient survey) was 24.32– 10.43 (range, 6–53) months, and
the mean GBE treatment duration was 23.81– 10.36 (range,
6–59) months. Significant differences were seen in mean
age, diastolic/systolic blood pressure, diabetes mellitus, and
hypertension prevalence rate between the anthocyanins and
GBE treatment groups (independent sample t-test, P values
< .001, .011, .007,< .001, and .001, respectively), but not in
the mean treatment duration and fasting blood glucose (in-
dependent sample t-test, P = .706, P = .225, respectively)
(Table 2).
In the anthocyanin treatment group (132 eyes of 132
patients), the mean baseline BCVA of all eyes was 0.16
(– 0.34) logMAR units. After anthocyanin treatment, the
mean BCVA for all eyes improved to 0.11 ( – 0.18) logMAR
units (paired sample t-test, P = .008). The HVF mean devi-
ation improved from - 6.44 ( – 7.05) to - 5.34 (– 6.42) after
anthocyanin treatment (paired sample t-test, P = .001)
(Table 3).
In the GBE treatment group (103 eyes of 103 patients),
the mean baseline BCVA of all eyes was 0.06 ( – 0.13)
logMAR units. After GBE treatment, the mean BCVA for
all eyes was 0.07 ( – 0.15) logMAR units (paired sample t-
test, P = .22). The HVF mean deviation improved from
- 5.25 ( – 6.13) to - 4.31 ( – 5.60) after GBE treatment
(paired sample t-test, P = .002) (Table 3).
The control group (97 eyes of 97 patients) showed a trend
of reduction in the mean BCVA from 0.07 ( – 0.11) logMAR
units to 0.13 (– 0.23) logMAR units after follow-up (paired
sample t-test, P = .009). The HVF mean deviation changed
from - 5.41 (– 4.64) to - 5.06 (– 6.32) (paired sample t-
test, P = .725) (Table 3).
The mean BCVA logMAR unit change was significantly
different among the anthocyanin treatment group
(- 0.05 – 0.21), the GBE treatment group (0.01 – 0.06), and
the nontreatment group (0.05 – 0.19) (one-way ANOVA,
P < .001) (Table 4). However, differences in the HVF mean
Table 1. Characteristics of All Patients
Variable Value
Number of patients 332 (332 eyes)
Gender 209 male, 123 female
Age (years)a 52.90– 13.74 (20–89)
Mean follow-up (months)a 23.82– 9.84 (12–59)
IOP (mm Hg)a 13.59– 3.03 (7–21)
Diastolic blood pressure (mm Hg)a 77.56– 7.97 (49–102)
Systolic blood pressure (mm Hg)a 121.95– 12.31 (90–163)
Fasting blood glucose (mg/dL)a 107.23– 22.95 (63–219)
Diabetes mellitus 78 patients (23.4%)
Hypertension 103 patients (30.9%)
aMean– SD (range).
IOP, intraocular pressure.
Table 2. Patient Characteristics
Anthocyanins (n= 132) Gingko biloba extract (n= 103) Control (n= 97) P valuea P valueb
Age (years)c 57.98– 10.52 46.98– 12.53 52.27– 16.04 < .001 < .001
Mean treatment duration (months)c 24.32– 10.43 23.81– 10.36 - - .706
Diastolic blood pressure (mmHg)c 78.24– 6.85 75.50– 7.00 78.82– 7.89 .006 .011
Systolic blood pressure (mm Hg)c 124.08– 10.58 119.83– 13.37 121.30– 12.99 .026 .007
Fasting blood glucose (mg/dL)c 110.82– 26.64 103.94– 16.78 103.92– 20.80 .156 .225
Diabetes mellitus 80 patients (60.6%) 90 patients (87.4%) 84 patients (86.6%) .814 < .001
Hypertension 76 patients (57.6%) 80 patients (77.7%) 73 patients (75.3%) .662 .001
aOne-way ANOVA.
bIndependent sample t-test between anthocyanins and Gingko biloba extract.
cMean– SD.
ANOVA, analysis of variance.
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deviation changes among the anthocyanin (0.73– 2.99), the
GBE (0.76 – 2.57), and nontreated (0.24– 5.62) groups
were not significant (one-way ANOVA, P = .55) (Table 4).
Differences in the mean BCVA logMAR unit change be-
tween the anthocyanin and GBE treatment groups were
significant (independent sample t-test, P = .004) (Table 4).
However, differences in the HVF mean deviation change
were not significant between the anthocyanins and GBE
treatment groups (independent sample t-test, P = .926)
(Table 4).
To describe the linear association between the final
BCVA and a set of exploratory variables, including the
systemic treatment (anthocyanins/GBE), age, diabetes
mellitus, hypertension, a generalized linear model was de-
veloped by a stepwise method. Our result demonstrated that
the final BCVA was affected only by systemic treatment
(anthocyanins P < .001, GBE P = .015) and not affected by
different demographics between the groups (age P = .402,
diabetes mellitus P = .114 and hypertension P = .357).
No ocular or systemic side effects were noted in any
patient during the follow-up.
DISCUSSION
Our results suggest that systemic administration of an-
thocyanins and GBE improves visual function in some in-
dividuals with NTG.
The anthocyanin treatment group showed improved BCVA
logMAR units and HVFmean deviation. In the GBE treatment
group, BCVA logMAR units were not changed significantly,
but the HVF mean deviation was improved. In the control
group, the BCVA logMAR units deteriorated, and the HVF
mean deviation was not changed after follow-up.
Although differences were significant for mean age, dia-
stolic/systolic blood pressure, diabetes mellitus, and hy-
pertension prevalence rates between the anthocyanins and
GBE treatment groups, the final BCVA was affected only by
systemic treatment and not by demographic factors of the
groups in a generalized linear analysis.
From these results, our study suggested that anthocyanins
and GBE might be effective for improving visual function in
patients with NTG. We think that the mechanisms of an-
thocyanins and GBE action are effects on blood circulation
and antioxidant properties.
Several studies examined the effects of anthocyanins and
GBE on blood circulation. In animal studies, anthocyanins
are beneficial for improving vascular tone and blood flow by
redistribution of microvascular blood flow and interstitial
fluid formation.28 Clinical trials in humans yielded similar
results. A study of 47 patients with various venous diseases,
giving 480mg/day of bilberry extract, resulted in a reduced
capillary flow as well as elimination of microstagnation and
blood stasis of the foot.29 A review of uncontrolled trials
from 1979 to 1985 on a total of 568 patients with venous
insufficiency of the lower limbs showed that anthocyanins
were effective in decreasing symptoms and improving both
venous microcirculation and lymph drainage.30 The results
of these studies indicate that the anthocyanins also can im-
prove ocular blood circulation.
Reports on the effects of GBE on ocular circulation in-
clude a prospective study of 11 healthy volunteers treated in
a random order with GBE 120mg/day for 2 days. GBE
significantly increased the end-diastolic velocity in the
ophthalmic artery, without changes in arterial blood pres-
sure, heart rate, or IOP.31 In another study, the same dose of
GBE for four weeks increased the microcircular blood
Table 3. Best-Corrected Visual Acuity, Visual Field Indices with Treatment
Anthocyanins (n= 132) Gingko biloba extract (n = 103) Control (n= 97)
Baseline Follow-up P valuea Baseline Follow-up P valuea Baseline Follow-up P valuea
Mean BCVA,
logMARb
0.16 – 0.34 0.11 – 0.18 .008 0.06 – 0.13 0.07 – 0.15 .22 0.07 – 0.11 0.13 – 0.23 .009
MD (dB)b - 6.44 – 7.05 - 5.34 – 6.42 .001 - 5.25 – 6.13 - 4.31 – 5.60 .002 - 5.41 – 4.64 - 5.06 – 6.32 .725
PSD (dB)b 5.00 – 3.97 4.68 – 4.02 .053 4.71 – 4.22 4.48 – 4.24 .242 4.74 – 3.85 4.59 – 3.61 .848
aPaired sample t-test.
bMean– SD.
logMAR, logarithm of the minimal angle of resolution; BCVA, best-corrected visual acuity; MD, mean deviation; PSD, pattern standard deviation.
Table 4. Changes in Best Corrected Visual Acuity (logMAR), Visual Field Indices Before and After Treatment
Anthocyanins (n = 132) Gingko biloba extract (n= 103) Control (n= 97) P valuea P valueb
Mean BCVA, logMARc - 0.05 – 0.21 0.01 – 0.06 0.05 – 0.19 < .001 .004
MD (dB)c 0.73 – 2.99 0.76 – 2.57 0.24 – 5.62 .55 .926
PSD (dB)c - 0.10 – 1.75 - 0.13 – 1.76 0.19 – 4.13 .64 .921
Change calculated as After-Before.
aOne-way ANOVA.
bIndependent sample t-test between anthocyanins and Gingko biloba extract.
cMean– SD.
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velocity, flow, and volume in healthy volunteers for four
weeks.32 In another study, GBE administration (160mg/day
for 4 weeks) increased the mean blood flow, volume, and
velocity in NTG patients.33
Many studies show that anthocyanins and GBE are potent
antioxidants. In animal studies, long-term daily intake of
anthocyanins in the diet affects antioxidant enzyme activity
and expression, and enhances oxidative markers in healthy
rats.34 The antioxidative properties of GBE are from its di-
rect radical-scavenging activity.35 GBE prevents oxidative
damage to mitochondria,36,37 exhibits neuroprotective
properties,38 and inhibits LDL oxidation.39
Another possible explanation of the beneficial effects of
anthocyanins and GBE in NTG patients is the effects of
anthocyanins and GBE on improvements in the cognitive
function.40 This effect has been demonstrated in patients
with cerebral vascular insufficiency.14 Cerebral small-vessel
ischemia is more common in NTG patients than in normal
subjects,41,42 so a reasonable assumption is that anthocyanin
or GBE administration improves BCVA and the mean de-
viation in VF indices via increased cerebral blood flow, thus
improving the ocular blood flow, and improving retinal
sensitivity, concentration, and alertness.43
The exact explanation for this effect is not clear, but GBE
and anthocyanins have anti-inflammatory properties,17,44
and several studies report that the chemopreventive activity
of anthocyanins is related to effects on signal transduction
and apoptosis.45,46
Some studies have demonstrated effects of anthocyanins
and GBE on visual function. Lee et al. reported that purified
high-dose anthocyanoside oligomer administration im-
proves nocturnal vision and clinical symptoms in myopia
subjects. After administering a purified high-dose antho-
cyanoside oligomer (100mg tablet, 85% anthocyanoside
oligomer) twice daily for 4 weeks, subjective symptoms and
objective contrast sensitivity improved in myopia subjects
with asthenopia.47
Quaranta et al. reported an effect of GBE on a pre-
existing visual field damage in patients with NTG. After
40mg of orally administered GBE, three times daily for 4
weeks, a significant improvement in visual field indices (the
mean deviation and the corrected pattern standard deviation)
was recorded without changes in the arterial blood pressure,
heart rate, or IOP.24 These properties support the therapeutic
value of anthocyanins and GBE in treating NTG.
This study mainly investigated objective rather than
subjective values, and the treatment duration was six months
or more, much longer than other studies. This article is the
first study on the direct effect of anthocyanins on NTG pa-
tients. In rare cases, mild gastrointestinal complaints,
headache, and allergic skin reactions have been reported
when GBE was used.48 A review of studies comprising over
2000 subjects taking anthocyanins reported mild side effects
affecting the gastrointestinal, cutaneous, or nervous sys-
tem,49 but in the present study, no ocular or systemic adverse
events related to the use of anthocyanins or GBE were re-
corded. The results are in accordance with a long-term
randomized clinical trial in which no significant difference
in the incidence of adverse events was found when antho-
cyanin-treated patients were compared with a control
group.14 The results of these studies suggest that anthocya-
nins and GBE were tolerable for most NTG patients.
However, our study had several limitations. First, because
of its retrospective nature, we cannot exclude the possible
effects of selection bias. However, we recruited consecu-
tive patients to minimize selection bias. Prospective vali-
dation of our results might be necessary. Second, our study
did not give the information on how long the effects of
anthocyanin and GBE administration last and how long
patients should take the systemic medication. Further study
is required to investigate the duration of the effect and the
optimal administration schedule for GBE and anthocyanin
treatment for NTG patients.
In conclusion, this study suggests that anthocyanins and
GBE could be effective for improving visual function in
patients with NTG. These results can help clinicians manage
patients with NTG.
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